5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H1 2019
SUMMARY
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Furthermore, this report also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H1 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Furthermore, this report also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - OVERVIEW
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - THERAPEUTICS DEVELOPMENT
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - THERAPEUTICS ASSESSMENT
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - COMPANIES INVOLVED IN THERAPEUTICS DEVELOPMENT
Arcus Biosciences Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec AG
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
MedImmune LLC
Novartis AG
Oric Pharmaceuticals Inc
Peloton Therapeutics Inc
Selvita SA
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - DRUG PROFILES
AB-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-708 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-1B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NZV-930 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-2828 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJ-4309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - DORMANT PRODUCTS
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - PRODUCT DEVELOPMENT MILESTONES
Featured News & Press Releases
Apr 02, 2019: Calithera Biosciences presents new preclinical data for CB-708 at AACR Annual Meeting 2019
Apr 01, 2019: Innate Pharma presents on its oncology drug candidate IPH-5301 at the american association of cancer research (aacr) 2019 annual meeting
Mar 25, 2019: InteRNA appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
Feb 28, 2019: Arcus Biosciences announces presentation on its oncology drug candidate AB680 at the 2019 American Association for Cancer Research Annual Meeting
Feb 27, 2019: Calithera Biosciences announces CB-708 preclinical data presentation at the AACR Annual Meeting 2019
Feb 06, 2019: Corvus presents updated clinical results from lead pipeline program CPI-006 at Immuno-Oncology 360° Conference
Jan 30, 2019: Corvus Pharmaceuticals to present updated biomarker and clinical data on lead development program CPI-006 at Immuno-Oncology 360° Conference
Jan 22, 2019: I-Mab Biopharma receives U.S. FDA IND clearance for proprietary CD73 antibody TJD5
Jan 08, 2019: Corvus announces enrollment in second arm of phase 1/1b dose-escalation trial of anti-CD73 antibody, CPI-006, focused on combination with CPI-444 Adenosine antagonist
Dec 26, 2018: TRACON Pharmaceuticals announces submission of IND application for TJ4309 (CD73 Antibody TJD5) for treatment of advanced solid tumors
Nov 10, 2018: Corvus Pharmaceuticals announces updated results from ongoing clinical studies of lead program, CPI-006, at SITC 33rd Annual Meeting
Nov 06, 2018: Corvus Pharmaceuticals to present CPI-006 at Investor & Analyst Event on November 10, 2018
Oct 25, 2018: Halozyme announces first clinical dosing in Bristol-Myers Squibb's phase 1 trial of BMS-986179 with Enhanze technology
Oct 22, 2018: Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker that can potentially identify patients most likely to benefit from therapies targeting adenosine pathway
Oct 04, 2018: Corvus Pharmaceuticals to present data on lead programme CPI-006 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - OVERVIEW
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - THERAPEUTICS DEVELOPMENT
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - THERAPEUTICS ASSESSMENT
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - COMPANIES INVOLVED IN THERAPEUTICS DEVELOPMENT
Arcus Biosciences Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec AG
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
MedImmune LLC
Novartis AG
Oric Pharmaceuticals Inc
Peloton Therapeutics Inc
Selvita SA
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - DRUG PROFILES
AB-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-708 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-1B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NZV-930 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-2828 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJ-4309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - DORMANT PRODUCTS
5' NUCLEOTIDASE (ECTO 5' NUCLEOTIDASE OR CD73 OR NT5E OR EC 3.1.3.5) - PRODUCT DEVELOPMENT MILESTONES
Featured News & Press Releases
Apr 02, 2019: Calithera Biosciences presents new preclinical data for CB-708 at AACR Annual Meeting 2019
Apr 01, 2019: Innate Pharma presents on its oncology drug candidate IPH-5301 at the american association of cancer research (aacr) 2019 annual meeting
Mar 25, 2019: InteRNA appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
Feb 28, 2019: Arcus Biosciences announces presentation on its oncology drug candidate AB680 at the 2019 American Association for Cancer Research Annual Meeting
Feb 27, 2019: Calithera Biosciences announces CB-708 preclinical data presentation at the AACR Annual Meeting 2019
Feb 06, 2019: Corvus presents updated clinical results from lead pipeline program CPI-006 at Immuno-Oncology 360° Conference
Jan 30, 2019: Corvus Pharmaceuticals to present updated biomarker and clinical data on lead development program CPI-006 at Immuno-Oncology 360° Conference
Jan 22, 2019: I-Mab Biopharma receives U.S. FDA IND clearance for proprietary CD73 antibody TJD5
Jan 08, 2019: Corvus announces enrollment in second arm of phase 1/1b dose-escalation trial of anti-CD73 antibody, CPI-006, focused on combination with CPI-444 Adenosine antagonist
Dec 26, 2018: TRACON Pharmaceuticals announces submission of IND application for TJ4309 (CD73 Antibody TJD5) for treatment of advanced solid tumors
Nov 10, 2018: Corvus Pharmaceuticals announces updated results from ongoing clinical studies of lead program, CPI-006, at SITC 33rd Annual Meeting
Nov 06, 2018: Corvus Pharmaceuticals to present CPI-006 at Investor & Analyst Event on November 10, 2018
Oct 25, 2018: Halozyme announces first clinical dosing in Bristol-Myers Squibb's phase 1 trial of BMS-986179 with Enhanze technology
Oct 22, 2018: Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker that can potentially identify patients most likely to benefit from therapies targeting adenosine pathway
Oct 04, 2018: Corvus Pharmaceuticals to present data on lead programme CPI-006 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Arcus Biosciences Inc, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Calithera Biosciences Inc, H1 2019
Pipeline by Corvus Pharmaceuticals Inc, H1 2019
Pipeline by Evotec AG, H1 2019
Pipeline by I-Mab Biopharma Co Ltd, H1 2019
Pipeline by Innate Pharma SA, H1 2019
Pipeline by InteRNA Technologies BV, H1 2019
Pipeline by MedImmune LLC, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Oric Pharmaceuticals Inc, H1 2019
Pipeline by Peloton Therapeutics Inc, H1 2019
Pipeline by Selvita SA, H1 2019
Dormant Projects, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Arcus Biosciences Inc, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Calithera Biosciences Inc, H1 2019
Pipeline by Corvus Pharmaceuticals Inc, H1 2019
Pipeline by Evotec AG, H1 2019
Pipeline by I-Mab Biopharma Co Ltd, H1 2019
Pipeline by Innate Pharma SA, H1 2019
Pipeline by InteRNA Technologies BV, H1 2019
Pipeline by MedImmune LLC, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Oric Pharmaceuticals Inc, H1 2019
Pipeline by Peloton Therapeutics Inc, H1 2019
Pipeline by Selvita SA, H1 2019
Dormant Projects, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Arcus Biosciences Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec AG
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
MedImmune LLC
Novartis AG
Oric Pharmaceuticals Inc
Peloton Therapeutics Inc
Selvita SA
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Arcus Biosciences Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec AG
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
MedImmune LLC
Novartis AG
Oric Pharmaceuticals Inc
Peloton Therapeutics Inc
Selvita SA
